Skip to main content

Table 5 Treatment-related adverse events

From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

  LX TBP
(N = 236) (N = 296)
  grade1–2 grade3–4 grade1–2 grade3–4
Neutropenia 24(10.2%) 5(2.1%) 87(29.4%) 19(6.4%)
Febrile neutropenia 4(1.7%) 0(0.0%) 20(6.8%) 4(1.4%)
Thrombocytopenia 12(5.1%) 1(0.4%) 25(8.4%) 3(1%)
Anemia 4(1.7%) 0(0.0%) 40(13.5%) 0(0.0%)
Nausea/Vomiting 60(25.4%) 0(0.0%) 56(18.9%) 8(2.7%)
Diarrhea 92(39.0%) 12(5.1%) 15(5.1%) 0(0.0%)
Cardiac toxicity 0(0.0%) 0(0.0%) 2(0.7%) 0(0.0%)
Rash or erythema 45(19.1%) 0(0.0%) 13(4.4%) 0(0.0%)
ALT/AST increased 28(11.9%) 0(0.0%) 32(10.8%) 27(9.1%)
Hand–foot syndrome 56(23.7%) 24(10.2%) 7(2.4%) 0(0.0%)
  1. Abbreviations: NCI CTCAE National Cancer Institute Common Terminology Criteria of Adverse Events